SurModics Financial Statements
SurModics Financial Information
| Company Type | Public Headquarters |
|---|---|
| Fiscal Year-End | September |
| Annual Report | Company Web Site |
| Investor Relations | Company Web Site |
This data is provided as per license from EDGAR Online
SurModics Income Statement
| 2007 | 2006 | 2005 | |
|---|---|---|---|
| Revenue ($ mil.) | 73.2 | 69.9 | 62.4 |
| Gross Profit ($ mil.) | 67.6 | 46.1 | 59.5 |
| Operating Income ($ mil.) | 9.9 | 36.2 | 3.0 |
| Total Net Income ($ mil.) | 3.3 | 20.3 | (8.3) |
| Diluted EPS (Net Income) | 0.18 | 1.09 | (0.45) |
SurModics Quarterly Statements
| Quarter Ending Mar 08 | Quarter Ending Dec 07 | Quarter Ending Sep 07 | |
|---|---|---|---|
| Revenue ($ mil.) | 25.7 | 23.8 | 21.3 |
| Gross Profit ($ mil.) | 24.4 | 21.0 | 19.1 |
| Operating Income ($ mil.) | 7.2 | 7.6 | (13.8) |
| Total Net Income ($ mil.) | 5.1 | 5.7 | (13.9) |
| Diluted EPS (Net Income) | 0.27 | 0.31 | (0.77) |
SurModics Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | 8.11 | 3.44 | 1.55 |
| Price/Earnings Ratio | 265.13 | 15.44 | 15.69 |
| Price/Book Ratio | 5.02 | 2.92 | 1.50 |
| Price/Cash Flow Ratio | 16.64 | 12.54 | 9.64 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed SurModics Financial Ratios
SurModics Competitive Intelligence
| Angiotech Pharmaceuticals | Biocompatibles | W.L. Gore | |
|---|---|---|---|
| Annual Sales ($ mil.) | 287.7 | 6.0 | 2,120.0 |
| Employees | -- | 92 | 8,400 |
| Market Cap ($ mil.) | 154.9 | -- | -- |
Competitive Landscape
